Astellas Pharma and Poseida Therapeutics, Inc. announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos")...
cTTP, an ultra-rare blood clotting disorder, presents life-threatening acute events and debilitating chronic symptoms. Untreated acute TTP ...
MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ:MNOV) and the Tokyo Stock Exchange (Code Number: 4875), has receiv...
Orchard Therapeutics, now under the stewardship of Kyowa Kirin, announces a historic milestone as the U.S. Food and Drug Administration (FDA) grants approv...
In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal a...
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have announced the acceptance of their Biologics License Application (BLA) for datopotamab...
Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved...
The expansion into Silicon Valley marks a strategic move for Ajinomoto Co., which seeks to support and collaborate with innovators across four key growth a...
Takeda unveiled promising topline results from a comprehensive Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patien...
Nikon Instruments Inc. (Nikon) is pleased to announce the establishment of the Nikon BioImaging Lab Lexington in Massachusetts, USA, where it will provide ...
Travere Therapeutics, Inc. announced that it has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endot...
In a significant move, Agappe and Fujirebio have revealed plans to launch these products in June 2024. The project has already achieved significant progres...
SyntheticGestalt, a research and development company specializing in the application of AI to the life sciences domain, and Enamine, the world's leading pr...
The two companies will collaboratively conduct early-stage research for these two programs. Elpiscience will also grant Astellas the right to add up to two...
© 2025 Biopharma Boardroom. All Rights Reserved.
